South Korea-based firm Dx&Vx will develop a bio-healthcare big data platform utilising artificial intelligence (AI) technology provided by LG CNS, a subsidiary of LG Corporation (also based in South Korea). This is the first case of LG CNS collaborating with a domestic biopharma company.

Dx&Vx is set to introduce an AI-driven digital medical and clinical data platform through its collaboration with LG CNS, which is a Google Cloud partner and key service provider. 

Through its cloud-based a precision medicine data platform, Dx&Vx has built a bio big data bridge system with Clidex CDx, a companion diagnostic (CDx) service, to provide a clinical decision support system (CDSS), Digital Therapeutics (DTx), and digital twin-based remote medicine, and will expand its service sales network to global markets such as new drug developers and pharmaceutical companies, medical institutions, and research institutes that need to provide precision medicine-based multi-omics analysis data and develop therapeutic drugs and related healthcare solutions. 

Starting with the joint development, Dx&Vx plans to strengthen its collaboration with LG CNS to develop innovative bio-healthcare solutions based on its biomedical big data platform.

Meanwhile, global pharmaceutical giant GSK recently invested $300 million in genomic analysis company 23andME to develop new drugs using genomic information, and the Korea Bio Association predicts that the global genomic market will grow to $13.55 billion in 2024.